Literature DB >> 8769380

The effects of the somatostatin analog octreotide on angiogenesis in vitro.

R Danesi1, M Del Tacca.   

Abstract

This study examined the in vitro antiangiogenic effects of the somatostatin analog octreotide on the growth of human HUV-EC-C endothelial cells and vascular cells from explants of rat aorta cultured on fibronectin-coated dishes or included in fibrin gel. A total 10(-9) mol/L octreotide reduced the mean uptake of 3H-thymidine by HUV-EC-C cells by 37% compared with controls. The 10(-8) mol/L concentration of octreotide inhibited the proliferation of endothelial and smooth muscle cells growing on fibronectin by 32.6% and reduced the sprouting of cells from the adventitia of aortic rings in fibrin by 33.2% compared with controls, as measured by tetrazolium bioreduction and image analysis, respectively. These results demonstrate that octreotide is an effective inhibitor of vascular cell proliferation in vitro.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769380     DOI: 10.1016/s0026-0495(96)90080-3

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

1.  A selective somatostatin type-2 receptor agonist inhibits neointimal thickening and enhances endothelial cell growth and morphology following aortic balloon injury in the rabbit.

Authors:  Natalie K Schiller; Alvin M Timothy; Harmeet S Aurora; I-Li Chen; David H Coy; William A Murphy; Donald L Akers; Vivian A Fonseca; Philip J Kadowitz; Dennis B McNamara
Journal:  Mol Cell Biochem       Date:  2002-11       Impact factor: 3.396

2.  Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.

Authors:  Valeria Cambiaghi; Eleonora Vitali; Diego Morone; Erika Peverelli; Anna Spada; Giovanna Mantovani; Andrea Gerardo Lania
Journal:  Endocrine       Date:  2016-07-12       Impact factor: 3.633

3.  Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors.

Authors:  Manu Jaggi; Sudhanand Prasad; Anu T Singh; R Praveen; Sarjana Dutt; Archana Mathur; Rajan Sharma; Neena Gupta; Rinku Ahuja; Rama Mukherjee; Anand C Burman
Journal:  Invest New Drugs       Date:  2008-01-24       Impact factor: 3.850

4.  Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts.

Authors:  Wei-Dong Jia; Ge-Liang Xu; Rong-Nan Xu; Hui-Chuan Sun; Lu Wang; Ji-Hai Yu; Jian Wang; Jian-Sheng Li; Zhi-Ming Zhai; Qiong Xue
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-14       Impact factor: 4.553

5.  Modulation of key signal transduction molecules by a novel peptide combination effective for the treatment of gastrointestinal carcinomas.

Authors:  Anu T Singh; Manu Jaggi; Sudhanand Prasad; Sarjana Dutt; Gurvinder Singh; Kakali Datta; Praveen Rajendran; Vinod K Sanna; Rama Mukherjee; Anand C Burman
Journal:  Invest New Drugs       Date:  2008-03-06       Impact factor: 3.850

Review 6.  Antiproliferative effects of somatostatin analogs in pituitary adenomas.

Authors:  Maria Chiara Zatelli; Daniela Piccin; Maria Rosaria Ambrosio; Marta Bondanelli; Ettore C degli Uberti
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

7.  Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium.

Authors:  R L Adams; I P Adams; S W Lindow; W Zhong; S L Atkin
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

8.  The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.

Authors:  Manuel D Gahete; David Rincón-Fernández; Mario Durán-Prado; Marta Hergueta-Redondo; Alejandro Ibáñez-Costa; Alejandro Rojo-Sebastián; Francisco Gracia-Navarro; Michael D Culler; Oriol Casanovas; Gema Moreno-Bueno; Raúl M Luque; Justo P Castaño
Journal:  Oncotarget       Date:  2016-09-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.